MOUNTAIN VIEW, Calif.
May 1, 2012
/PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in
Deutsche Bank 37th Annual Healthcare Conference
Tuesday, May 8
8:40 a.m. ET
Bank of America Merrill Lynch 2012 Healthcare Conference
Tuesday, May 15
3:40 p.m. PT
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at
. A replay also will be available within 24 hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the potential acute treatment of migraine. The U.S. Food and Drug Administration reviewed the New Drug Application for LEVADEX and on
March 26, 2012
, the Company received a Complete Response letter. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and
. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at
MAP Pharmaceuticals, Inc.650-386-3122
SOURCE MAP Pharmaceuticals, Inc.